Is the common 677 C→T mutation in the methylenetetrahydrofolate reductase gene a risk factor for neural tube defects? : 14 by Put, N.M.J. van der et al.






The following full text is a publisher's version.
 
 





Please be advised that this information was generated on 2017-12-05 and may be subject to
change.
Q S Med 1997; 90:111-115
Original papers
Is the common 677C—>T mutation ¡n the 
methylenetetrahydrofolate reductase gene a risk factor for 
neural tube defects? A meta-analysis
N.M.J. VAN DER PUT,1 T.K.A.B. ESKES2 and H.J. BLOM1
From the Departments o f1 Pediatries and2Obstetrics & Gynecology, University Hospital 
Nijmegen, The Netherlands
Received 28 October 1996
Summary
The common 677C->T mutation ( + ) in the 
5,10-methylenetetrahydrofolate reductase gene, 
resulting in decreased activity of the enzyme, has 
been associated with spina bifida neural tube defects 
(NTD). We combined all known Dutch control 
groups, a total of 1273 individuals, and found a 
prevalence of the 677C-+T mutation of 8.4%. When 
compared with the frequencies in 55 SB patients 
and to mothers with a child with SB their parents, 
this gave an OR of 1.9 [95% Cl 1*1 -3.3] for mothers 
and an OR of 1.5 [95% Cl 0.74-3.1] for patients. 
The frequency of this mutation and its associated 
risk for NTD may be population-dependent 
However, the frequencies of the 677C->T mutation
in different national and international control groups 
are almost all in the same range. We therefore 
combined the observed frequencies of the 677C-*T 
mutation in all reported studies. The mutation was 
present in 9.2% of controls, resulting in ORs for all 
reported NTD patients and their parents of: 1.7 
[95% Cl: 1.1-2,6]; 1.8 [95% Cl: 1.1-3.1] and 1.9 
[95% Cl: 1.3-2.8] for mothers (combined preval­
ence 14.5%), fathers (combined prevalence 15.5%) 
and NTD patients (combined prevalence 16.4%), 
respectively, vs, all international controls. This meta­
analysis confirms that the 677C-*T mutation is a 
genetic risk factor for NTD.
Introduction
In our previous studies, a common 677C->T muta­
tion in the 5,10-methylenetetrahydrofolate reductase 
(MTHFR) gene, resulting in reduced enzyme activity 
and an impaired homocysteine/folate metabolism, 
was investigated as a genetic risk factor for spina 
bifida (SB).1'2 Homozygosity for the alanine to valine 
substitution ( + /+ ) was observed in 4.8% of the 
controls, vs. 15.7% of the mothers, 10.0% of the 
fathers and 12.7% of the affected children of the 
families with SB offspring.1 Significant odds ratios 
(ORs) of 3,7 for mothers and 2.9 for SB patients
were observed in the first study, demonstrating an 
abnormality in folate metabolism as a genetic risk 
factor for SB. Our findings have been confirmed by 
two other studies on neural tube defects (NTD).3'4 
Recently, we showed that the OR increased to 4.1 
[95% Cl 1.5-11.1] if the mother has a +/ + 
genotype and her child a +/- genotype, and even 
to 6.1 [95% Cl 1.0-35.5] if both the mother and her 
child have a + /+  genotype.2
MTHFR catalyses the reduction of 5,10-methyl- 
enetetrahydrofolate to 5-methyltetrahydrofolate, a
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cosubstrate for the remethylation of homocysteine to 
methionine. The 677C ^T  mutation causes reduced 
MTHFR activity and a protein with thermoiabile 
properties and is associated with elevated plasma 
homocysteine levels and a redistribution of folates, 
namely elevated red-cell folate (RCF) and lowered 
plasma folate.1'2 This mutation explains a substantial 
part of the observed elevated plasma homocysteine 
levels in mothers of children with NTD. Although 
mean homocysteine levels were increased in those 
homozygous for this mutation, not all + /+  subjects 
had elevated homocysteine levels. Plasma folate is 
a very strong determinant of plasma homocysteine 
in individuals with the + /+  genotype. It has been 
suggested that individuals who are homozygous for 
the 677C-*T mutation in the MTHFR gene have 
higher nutritional folate requirements.2
We reported previously that about 5% of the 
Dutch control group had the mutation in the homozy­
gous form,1 whereas an Irish study observed a 
frequency of 6,1% and an Atlanta group a frequency 
of 5% in their controls.3,4 However, the prevalence 
of homozygosity for this mutation is also reported to 
be 12% in French Canadians,5 16,3% in Italians/ 
10.7% in White Australians/ and (12% among British 
controls, 2% in Japanese and 9% in Utah Mormons).8 
In this study, we examined whether these reported 
prevalences of the 677C~>T mutation in the MTHFR 
gene are population-dependent. If they were, the risk 
of NTD associated with this mutation might also be 
population-dependent All known Dutch control 
groups were combined to estimate the prevalence of 
the 677C->T mutation in the Dutch population. 
Furthermore, all published data of control groups 
and NTD families were pooled to study the implica­
tions of this common mutation for the risk of NTD.
Methods
SB patients and their parents were recruited in 
collaboration with the Dutch society for patients 
with central nervous system defects and their parents 
(BOSK).1 The study group consisted, as reported 
previously,1,2 of 70 mothers, 60 fathers and 55 
children with SB, Children younger than 3 years 
were excluded.
For a more reliable estimate of the prevalence of 
the 677C—>T mutation among the Dutch population, 
the control group was composed of controls from 
several published and unpublished Dutch studies. 
Some 440 controls were from published studies: 318 
controls (207 and 109 of whom had been used in 
our previous studies);1,9 99 controls10 and 23 con­
trols,11 and 833 as yet unpublished controls. All the 
mutation analyses were performed by our laboratory. 
By combining these different studies, we obtained a
large control group of 1273 unrelated Dutch indi­
viduals of both sexes with no history of NTD.
The investigated mutation in the MTHFR gene is 
a C to T substitution at base pair 677, altering an 
alanine to a valine residue. The prevalence of this 
mutation was investigated, as reported before.1
Statistics
Crude odds ratios (OR) and 95% confidence intervals 
(95% CIs) were calculated to estimate the relative 
risk of the 677C—>T mutation for NTD offspring.
Results
O f 1273 Dutch controls, 107 (8.4%; 95% Cl 
6.9%-10.0%) had a + /+  genotype for the 677C-+T 
mutation (Table 1). The +/- genotype was observed 
in 537 and the genotype in 629 control. The 
observed frequency of the + allele was 0.3.
Figure 1 shows the frequencies and 95% CIs of 
the 677C-+T mutation among the different Dutch 
controls and other international studies. Since there 
were no significant differences between the Dutch 
control groups, they were combined into one total 
Dutch control group.
We calculated ORs by comparing the prevalence 
of the 677C—»T mutation in the combined Dutch 
control groups and in 55 SB patients and their 
parents. The ORs were: mothers (n =  70), 1.9 [95% 
Cl 1.1-3.3]; fathers (n =  60), 1.1 [95% Cl 0.5-2.4]; 
and patients (n =  55), 1.5 [95% Cl 0.7-3.1], all vs. 
combined Dutch controls (n =  1273).
A  large international control group was con­
structed by combining Dutch and other reported 
control groups.1-12 The + /+  genotype was found 
in 235/254 international controls was found, giving 
a frequency of 9.2% (95% Cl 8.1 %—10.4%) 
{Figure 1). Only the Italian control group6 had a 
significantly higher prevalence of this common muta­
tion than the combined international control group.
The prevalences of the + /+  genotype among 
NTD patients1'3,4,8 and their mothers1,3,6/8 and 
fathers1'3,8 were also calculated from combined 
groups. Overall, 36/219 NTD patients, 24/166 
mothers and 17/110 fathers had a + /+  genotype. 
We calculated ORs for the combined NTD patients 
and their parents compared to the total international 
control group. These were: mothers, 1.6 [95% Cl 
1.1-2.3]; fathers, 1,7 [95% Cl 1.1-3.6] and patients, 
1.8 [95% Cl 1.3-2.5], all vs, all international 
controls.
Discussion
The present data confirm our previous observations172 
that the 677C ^T  mutation in the MTHFR gene is a
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Table 1 Prevalence of thermolabile MTHFR due to the 677C-*T mutation among Dutch and international controls and 
NTD patients and their parents
Control groups Group size +/+ frequency (n) Range 95% Cl
Dutch controls
Unpublished Xa 833 8.9% (74) 7.0-10.8%
Put et a/.1 318 7.9% (25) 4.7-11.0%
Verhoef et a/.10 99 7.1% (7) 2.0-12.1%
Engbersen et a/.11 23 4.3% (1) 0-13.0%
Total Dutch controls 1273 8.4% (107) 6.8-10.0%
Reported international controls
Whitehead et al.3 99 6.1% (6) 2.0-10.1%
Ou ei a/.4 109 4.6% (5) 0.9-8.3%
Frosst et a/.5 57 12.3% (7) 3.5-21.1%
Franchis et al.6 289 16.3% (47) 11.8-20.8%
Wilcken & Wang7 225 10,7% (24) 6.7-14.7%
Papapetrou et a/.8 199 12,1% (24) 7.7-16.6%
Papapetrou et a/.8 44 2,3% (1) 0-6.8%
Papapetrou et a/.8 45 8,9% (4) 0-17.8%
Kang et a/.12 202 5.0% (10) 2.0-7.9%
Total all controls 2542 9.2% (235) 8.1-10.4%
Reported NTD cases
Put ef al.1 55 12.7% (7) 3.6-21.8%
Whitehead et a I,3 82 17.6% (15) 9.8-26.8%
Ou et al.4 41 22.0% (9) 9.8-34.1%
Papapetrou et a/.8 41 12.2% (9) 2.4-22.0%
Total all NTD cases 219 16.4% (36) 11.4-21.5%
Reported mothers
Put et a/.1 70 15.7% (11) 7.1-24.3%
Whitehead et al.3 32 18.8% (6) 6.3-31,3%
Franchis et al.6 28 7,1% (2) 0-17.9%
Papapetrou et al.8 36 13.9% (5) 2,8-25.0%
Total all mothers 166 14.5% (24) 9.0-19.9%
Reported fathers
Put et al.1 60 10.0% (6) 1.7-18.3%
Whitehead ef al.3 24 29.2% (7) 12.5-45.8%
Papapetrou ei a/.8 26 15,4% (4) 3.8-26.9%
Total all fathers 110 15.5% (17) 8.2-22.7%
$
Figure 1. Prevalence of the 677C->T mutation among different control groups. The 95% CIs are shown by arrows. Reported 
prevalences among international control groups are shown as stars, those in Dutch controls are indicated by X, and the 
number indicates the relevant reference. Xa represents the prevalence among unpublished Dutch controls. The combined 
prevalence of all Dutch controls is shown as ■ and the combined frequency among all Dutch and reported international 
control groups by O .
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genetic risk factor for NTD. The mutation analysis 
shows that homozygosity for this mutation is relevant 
not only in mothers, but also in the affected patients, 
and therefore their fathers. The risk of NTD increases 
if both the mother and her child have a +/+ 
genotype,2 supporting this finding.
The observed ORs of 1.5-1.8 in patients and 
1.6-1.9 in their mothers are modest, but from the 
point of view of general health care, the observed 
risk factors are of great importance because of the 
high prevalence of homozygous mutants of about 
9% in the general population.
The 677C—>T mutation causes an alanine to valine 
substitution in the MTHFR protein. This amino acid 
change results in decreased MTHFR activity in both 
the homozygous and the heterozygous state.1 
Individuals with a + /+  genotype demonstrate elev­
ated plasma homocysteine at low folate levels, 
whereas those with a +/- or -/- genotype have 
normal plasma homocysteine levels, indicating that 
the + /+  genotype can cause a defective homocyst­
eine methylation to methionine.1,2 Embryonic tissues 
grow extremely rapidly, with high requirements for 
methyl groups from S-adenosylmethionine, which 
are provided by folate-dependent homocysteine 
remethylation. Individuals with a + /+  genotype 
may well need more- folate to provide adequate 
amounts of methyl groups. While during early preg­
nancy fetal DNA is hypomethylated,13 this relatively 
mild deficiency in folate metabolism may become 
important in pregnancy, when large amounts of 
methyl groups are required to methylate DNA. 
Disrupted gene expression, due to the undermethyl- 
ation of parts of a gene, can explain how a relatively 
mild defect initiates the development of severe 
abnormalities in the embryo.
The 677C-*T mutation analysis of all control 
groups known to us revealed few significant differ- 
ences in population-specific frequencies; only one 
Italian study recorded a frequency that was signific­
antly different from most, but not all, other control 
groups. The prevalences of the mutation among all 
different reported NTD patients and their parents 
were not significantly different between the stud- 
ies.1'3,4,6'8 Combining all international data on control 
groups and families with SB offspring, resulted in a 
twofold increased risk of the mutation for NTD. This 
increased risk was not only associated with the 
genotype of the mother but also with that of her 
child, and thus by implication the genotype of 
the father.
In conclusion, the observed frequencies of the 
677C->T mutation in the MTHFR gene in the differ­
ent control groups are within the same range, except 
for one Italian study.6 Large numbers of controls and 
NTD families are required for a reliable estimate of 
the prevalence of this mutation. From this meta­
analysis we conclude that homozygosity for this 
common mutation results in a twofold increased risk 
of NTD.
Acknowledgements
We thank S. Heil, L. van den Heuvel, M. den Heijer, 
L. Kluijtmans, E. Mariman, E. van der Molen, 
J. Smeitink, E. Steegers, R. Steegers-Theunissen, 
E. Stevens, F. Trijbels, P. Verhoef and F. Rosendaal 
for their valuable contribution, This study was sup­
ported by grant no 93-1104 from the Prinses Beatrix 
Fonds, The Netherlands.
References
1. van der Put NM], Steegers-Theunissen RPM, Frosst P,Trijbels 
FJM, Eskes TKAB, van den Heuvel IP, Mariman ECM, den 
HeyerM, Rozen R, Blom HJ. Mutated
methylenetetrahydrofolate reductase as a risk factor for 
spina bifida. Lancet 1995; 346:1070-1.
2. van der Put NMJ, van den Heuvel LP, Steegers-Theunissen 
RPM, Trijbels FMJ, Eskes TKAB, Mariman ECM, den Heyer 
M, Blom HJ. Decreased methylenetetrahydrofolate 
reductase activity due to the 677C-+T mutation in families 
with spina bifida offspring. JMM 1996; 74:691 -4.
3. Whitehead AS, Gallagher P, Mills JL, Kirke PN, Burke H, 
Molloy AM, Weir DG, Shields DC, Scott JM. A genetic 
defect in 5,10-methylenetetrahydrofolate reductase in 
neural tube defects. Q J Med 1995; 88:763-6.
4. Ou CY, Stevenson RF, Brown VK, Schwartz CE, Allen WP, 
Khoury M, Oakley GP, Adams Mj. C677T homozygosity 
associated with thermolabile
5,10-methylenetetrahydrofolate reductase as a risk factor for 
neural tube defects. Am J Hum Genet 1995; 57 (suppl): 
A223,
5. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, 
Matthews RG, Boers GjH, den Heyer M, Kluytmans LAJ, van 
den Heuvel LP, Rozen R. A candidate genetic risk factor for 
vascular disease: a common mutation in 
methylenetetrahydrofolate reductase. Nature Genet 1995; 
10:111-13.
6. de Franchis R, Sebastio G, Mandate C, Andria G, 
Mastroiacovo P. Spina bifida, 677C-*T mutation, and role 
of folate. Lancet 1995; 346:1703
7. Wilcken DEL, Wang XL, Relevance to spina bifida of 
mutated methyfenetetrahydrofolate reductase. Lancet 1996; 
347:340.
8. Papapetrou C, Lynch SA, Burn J, Edwards YH. 
Methylenetetrahydrofolate reductase and neural tube 
defects. Lancet 1996; 348:58.
9. Kluijtmans LAJ, van den Heuvel LPWJ, Boers GHJ, Frosst P, 
Stevens EMB, van Oost BA, den Heyer M, Trijbels FJM, 
Rozen R, Blom HJ. Molecular genetic analysis in mild 
hyperhomocysteinemia: A common mutation in the 
methylenetetrahydrofolate reductase gene is a genetic risk 
factor for cardiovascular disease. Am j  Hum Genet'\996; 
58:35-41.
10. Verhoef P, Kok FJ, Kluijtmans LAJ, Blom HJ, Refsum H,
U el and PM, Kruyssen DACM. Combination of mutated 
methylenetetrahydrofolate reductase and low folate status is
Genetic risk factor in NTD 115
associated with high plasma total homocysteine.
(submitted).
1. Engbersen AMT, Franken DC, Boers GHJ, Stevens EMB, 
Trijbels FJM, Blom HJ. Thermolabile
5,10-methylenetetrahydrofolate reductase as a cause of mild 
hyperhomocysteinemia. Am J Hum Genet 1995;
56:142-50.
2. Kang S-S, Wong PWK, Susmano A, Sora J, Norusis M,
Ruggie N. Thermolabile methylenetetrahydrofoiate 
reductase: an inherited risk factor for coronary artery 
disease. Am )  Hum Genet 1991; 48:536-45.
13. Monk M, Boubetik M, Lehnert S. Temporal and regional 
changes in DNA methyiation in the embryonic, 
extraembryo nie and germ cell lineages during mouse 
embryo development Development 1987; 99:371-82.
